0001104659-17-041909.txt : 20170628 0001104659-17-041909.hdr.sgml : 20170628 20170628060108 ACCESSION NUMBER: 0001104659-17-041909 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170623 FILED AS OF DATE: 20170628 DATE AS OF CHANGE: 20170628 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics Plc CENTRAL INDEX KEY: 0001703287 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 56 FITZWILLIAM SQUARE CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: 6108166640 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Plc DATE OF NAME CHANGE: 20170407 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sender Gary CENTRAL INDEX KEY: 0001659085 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38132 FILM NUMBER: 17933657 MAIL ADDRESS: STREET 1: C/O SYNERGY PHARMACEUTICALS INC. STREET 2: 420 LEXINGTON AVE CITY: NEW YORK STATE: NY ZIP: 10020 4 1 a4.xml 4 X0306 4 2017-06-23 0 0001703287 Nabriva Therapeutics Plc NBRV 0001659085 Sender Gary 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406 0 1 0 0 Chief Financial Officer Ordinary Shares 2017-06-23 5 J 0 E 2200 0 A 2200 D Stock Option 2017-06-23 5 J 0 E 88800 0 A 2026-05-30 Ordinary Shares 88800 88800 D Stock Option 2017-06-23 5 J 0 E 113000 0 A 2027-02-06 Ordinary Shares 113000 113000 D Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. The exercise price is 6.50 Euro. This option was granted on May 31, 2016. Vesting began on May 31, 2016 and ends on May 31, 2020. Twenty-five percent (25%) of the option will vest on May 31, 2017, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period. The exercise price is 7.963 Euro. This option was granted on February 7, 2017. Vesting began on February 28, 2017 and will end on February 28, 2021. Twenty-five percent (25%) of the option will vest on February 28, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period. /s/ Gary L. Sender 2017-06-27